HI
VRTX icon

Horizon Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Horizon Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9M Buy
24,435
+13,060
+115% +$6.09M 0.12% 139
2025
Q4 		$5.16M Buy
11,375
+2,181
+24% +$940K 0.07% 243
2025
Q3 		$3.6M Buy
9,194
+1,352
+17% +$565K 0.05% 298
2025
Q2 		$3.49M Buy
7,842
+2,793
+55% +$1.29M 0.06% 258
2025
Q1 		$2.45M Buy
5,049
+80
+2% +$37.3K 0.07% 172
2024
Q4 		$2M Buy
4,969
+86
+2% +$39.9K 0.06% 186
2024
Q3 		$2.27M Sell
4,883
-55
-1% -$26.4K 0.06% 159
2024
Q2 		$2.31M Sell
4,938
-134
-3% -$58.2K 0.06% 143
2024
Q1 		$2.12M Buy
5,072
+182
+4% +$76.9K 0.06% 155
2023
Q4 		$1.99M Buy
4,890
+403
+9% +$149K 0.06% 149
2023
Q3 		$1.56M Buy
4,487
+56
+1% +$19.6K 0.05% 137
2023
Q2 		$1.56M Sell
4,431
-196
-4% -$66K 0.04% 138
2023
Q1 		$1.46M Sell
4,627
-2,636
-36% -$791K 0.04% 137
2022
Q4 		$2.1M Sell
7,263
-3,638
-33% -$1.11M 0.06% 132
2022
Q3 		$3.16M Buy
10,901
+7,448
+216% +$2.14M 0.1% 83
2022
Q2 		$973K Sell
3,453
-7,917
-70% -$2.12M 0.03% 187
2022
Q1 		$2.97M Buy
11,370
+1,904
+20% +$452K 0.08% 113
2021
Q4 		$2.08M Buy
9,466
+6,725
+245% +$1.31M 0.06% 141
2021
Q3 		$497K Sell
2,741
-839
-23% -$164K 0.01% 324
2021
Q2 		$722K Buy
3,580
+1,128
+46% +$236K 0.02% 258
2021
Q1 		$527K Buy
+2,452
New +$539K 0.02% 285
2020
Q4 		– Sell
-7,238
Closed -$1.97M – 394
2020
Q3 		$1.97M Buy
7,238
+2,380
+49% +$657K 0.07% 127
2020
Q2 		$1.41M Buy
4,858
+1,640
+51% +$445K 0.03% 191
2020
Q1 		$766K Buy
3,218
+393
+14% +$90.2K 0.04% 147
2019
Q4 		$619K Buy
2,825
+1,233
+77% +$250K 0.03% 247
2019
Q3 		$270K Sell
1,592
-87
-5% -$15.4K 0.01% 280
2019
Q2 		$308K Buy
1,679
+348
+26% +$60.8K 0.01% 373
2019
Q1 		$245K Buy
+1,331
New +$246K 0.01% 320

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Horizon Investments's VRTX Position: Q1 2026 in Review

Horizon Investments increased its Vertex Pharmaceuticals (VRTX) stake by 115% in Q1 2026, buying an estimated $6.09M and bringing the position to 24,435 shares worth $10.9M. The position accounts for 0.12% of the portfolio, ranked #139.

Horizon Investments first reported a position in VRTX in Q1 2019 and has held it in 28 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Horizon Investments held 24,435 shares of Vertex Pharmaceuticals worth $10.9M as of Q1 2026.
  • Horizon Investments bought 13,060 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.09M.
  • Vertex Pharmaceuticals made up 0.12% of Horizon Investments's portfolio in Q1 2026, its #139 holding.
  • Horizon Investments first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.